KSR (kinase suppressor of Ras) has been proposed as a molecular scaffold regulating the Raf/MEK/ERK kinase cascade. KSR is phosphorylated on multiple phosphorylation sites by associated kinases. To identify potential mechanisms used by KSR to regulate ERK activation, green fluorescent protein was fused to intact and mutated KSR constructs lacking specific phosphorylation sites, and the subcellular distribution of each construct was observed in live cells. Mutation of a subset of KSR phosphorylation sites caused the redistribution of KSR to the nucleus. To determine whether intact KSR is normally imported to the nucleus, REF-52 fibroblasts expressing KSR were treated with 10 nM leptomycin B, which inhibits Crm1-dependent nuclear export. KSR accumulated in the nucleus within 2 h of treatment with leptomycin B, suggesting that KSR cycles continuously through the nucleus. Nuclear import of KSR was blocked by mutations that inhibit the interaction of KSR with MEK. Coexpression of fluorescent forms of KSR and MEK in cells revealed that each protein promoted the localization of the other in the cytoplasm. These data indicate that the subcellular distribution of KSR is dynamically regulated through phosphorylation and MEK interaction in a manner that may affect signaling through ERK.
termed the MAPK pathway. Genetic screens for modifiers of Ras signaling in Caenorhabditis elegans and Drosophila melanogaster identified KSR as a positive regulator of Ras signaling, functioning between Ras and Raf or in a pathway parallel to Raf (4 -6) . Consistent with these epistasis experiments, structure/function analysis revealed that a cysteine-rich region (CA3) in KSR enhances the positive effects of Ras on Raf (7, 8) . However, KSR may also regulate other points in the MAPK pathway. KSR binds Raf, MEK, and ERK (7, 9 -12) . Interaction of the KSR kinase domain with MEK is biologically important, as a mutation that prevents the interaction of KSR and MEK (12, 13 ) also disrupts KSR function in C. elegans (5) . These data have led to the hypothesis that KSR functions as a scaffold to coordinate these components of the kinase cascade (7, 9 -12, 14) . Characteristic of a molecular scaffold (15) , overexpression of ectopic KSR inhibits signaling through the MAPK cascade (7, 11, 14, 16) .
Regulating the subcellular distribution of signaling components is one way a scaffold can control signaling through an intracellular pathway. Translocation of Raf, MEK, and ERK to different subcellular compartments is essential to their normal function. Raf interacts with Ras in a GTP-dependent manner and translocates to the plasma membrane (17) (18) (19) (20) (21) (22) (23) . ERKs facilitate gene transcription by translocating to the nucleus, phosphorylating transcription factors, and stimulating their activity (24 -27) . Similar to ERKs, MEK translocates to the nucleus upon stimulation with mitogens or serum (28, 29) . Evidence also suggests that MEK and ERK, rather than localizing exclusively to the cytoplasm in resting cells, are continuously cycling in and out of the nucleus (30, 31) . Nuclear export of ERK involves a MEK-dependent active transport mechanism (32) . The ability of KSR to interact with Raf, MEK, and ERK and observations that loss-of-function mutations in KSR specifically disrupt KSR/MEK interaction raise the possibility that KSR may affect signaling through the MAPK cascade by altering the subcellular distribution of one or more signaling components.
To better understand the mechanism by which KSR regulates the MAPK pathway, we used a GFP-KSR fusion protein to determine the subcellular distribution of KSR in live cells. We found that KSR was localized to the cytoplasm in quiescent cells, but, like MEK and ERK, continuously cycled through the nucleus. Mutations in KSR that altered its ability to bind MEK also inhibited nucleocytoplasmic transport of KSR. We also found that phosphorylation of KSR regulated its nucleocytoplasmic distribution, but did not impair its association with MEK. This study suggests a link between the ability of KSR to translocate to the nucleus, to bind MEK, and to regulate ERK activation.
MATERIALS AND METHODS
Cell Culture-Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and incubated at 37°C. 293T and REF-52 cells were grown in a 5% CO 2 atmosphere.
Construction of KSR Expression Plasmids-The addition of the FLAG epitope tag to the COOH terminus of KSR and the construction of pCMV5KSR.R589M, pCMV5KSR.T411V, pCMV5KSR.S518A, pCMV5KSR.S392A, and pCMV5KSR.T274V were described previously (14, 33) . To create pCMV5KSR.S518A/T411V, pCMV5KSR.S518A and pCMV5KSR.T411V were digested with BstXI, and the appropriate fragments were ligated together. pCMV5KSR.T274V/T411V was created by digesting pCMV5KSR.T274V and pCMV5KSR.T411V with BamHI and ligating together. 4mut is S518A/T274V/S392A/T411V. 5mut adds S297A; 6mut adds S190A; and 9mut adds S320A, S429A, S430A, S431A, S434A, and S435A. These constructs were created as described previously (33) . pCMV5KSR.C809Y was created using the method described above and primer 5Ј-GGCGAGATCCTGTCTGCATACTGG-GCTTTCGATCTGC-3Ј (deletes the BglI site). Using pCMV5KSR.9mut, Val 274 was reverted to Thr using primer 5Ј-GCTGAAGCCACCAAGGA-CACCCCCACCGCC-3Ј (deletes the created AvrII site) either singly or in combination with reversion of Ala 392 to Ser using primer 5Ј-CGGAG-GACAGAGTCTGTCCCGTCAGATATC-3Ј (destroys the created KpnI site) to create 9mutA392S, 9mutV274T, and 9mutV274T/A392S. The remaining double mutants were created by PCR mutagenesis using one mutant as a template for mutation of the second site.
Construction of GFP-KSR Fusion Proteins and Nuclear Targeted Proteins-
The GFP-KSR fusion constructs were created by digesting pEGFP-C1 (CLONTECH) and the construct in pCMV5 with EcoRI and KpnI (wild-type KSR and R589M), XbaI (C809Y), BamHI (9mut), or SalI (T274V, S392A, S518A, T411V, S518A/S392A, T274V/S297A,  T274V/S518A, S297A/S392A, S392A/T411V, 4mut, 5mut, 6mut, T274V/  S392A, S518A/T411V, T274V/T411V, 9mutA392S, 9mutV274T , and 9mutV274T/A392S) and ligating the appropriate fragments together.
The sequence PKKKRKV was fused to the carboxyl terminus of KSR, KSR.R589M, and KSR.C809Y using primer 5Ј-GACTACAAGGACGA-CGATGACAAGCCTAAGAAGAAGCGGAAGGTCGACTAGGGTACCG-G-3Ј (34) . The primer sequence contains a SalI restriction site for screening.
Construction of YFP-MEK Fusion Proteins-The sequence of MEK1 was obtained by designing primers for PCR of the sequence from pcDNA1MEK1 (gift from Nick Grammatakakis), with enzyme sites HindIII (5Ј-end) and BamHI (3Ј-end). MEK1 was then subcloned into pEYFP-C1 using HindIII/BamHI. To construct YFP-MEK1.⌬NES, the reported NES (amino acids 32-44) (28) was deleted from YFP-MEK1 by PCR mutagenesis. The forward primer sequence (and its reverse complement) used was 5Ј-CAGCTCGGCCGAGACCAACCTGGAGCAG-CAGCGGAAGCGGCTAGAGGCCTTTC-3Ј, and ALQKKLEELELDE (nucleotides 134 -174) of MEK1 was deleted. The XhoI site was deleted, and the absence of this site was used to identify the appropriate construct.
The coding region for CFP was excised from the promoterless vector pECFP-1 and substituted for GFP in the pEGFP-C1 vector using the enzyme sites AgeI and BsrGI. CFP fusion proteins with KSR were constructed as described above to create GFP-KSR fusion proteins.
ERK Assay-293T cells were transfected with the indicated cDNAs using calcium phosphate (33) . This procedure resulted in transfection efficiencies in 293T cells near 90%. Activation of the ERK MAPK was achieved by transfection of constitutively active Raf (Raf-CAAX). The cells were lysed, and clarified cell lysates were immunoprecipitated using anti-ERK1 and anti-ERK2 antibodies (Santa Cruz Biotechnology). The ERK assay was performed using MBP as a substrate (14) . Reactions were stopped by the addition of sample buffer and heating to 110°C for 3 min and then subjected to SDS-polyacrylamide gel electrophoresis on a 12% gel. Radiolabeled MBP was quantified using storage phosphor technology (Molecular Dynamics, Inc.).
Western Blot Analysis-Proteins were transferred to polyvinylidene difluoride membranes, and Western blots were developed using anti-FLAG antibody M2 (1:2000; Kodak Scientific Imaging Systems), antic-Raf antibody (1:1000; Transduction Laboratories), anti-GFP antibody (1:500; CLONTECH), anti-MEK antibody (1:1000; Transduction Laboratories), or phospho-specific anti-ERK antibody (1:1000; New England Biolabs Inc.). Blots were developed with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium using goat anti-mouse or goat anti-rabbit secondary antibody conjugated to alkaline phosphatase.
Cell Microinjection-REF-52 cells were either microinjected using an Eppendorf Transjector 5246 system or transfected using Superfect (QIAGEN Inc.) according to the manufacturers' instructions. Microinjected cells were serum-starved for 18 h before microinjection with 100 ng of plasmid/l and examined by fluorescence microscopy 5 h after microinjection using the appropriate filters (Nikon, Inc.). Transfected cells were analyzed by fluorescence microscopy with the appropriate filter 18 h after transfection.
RESULTS

KSR Undergoes
Nucleocytoplasmic Transport-To gain insight into the molecular mechanism by which KSR regulates ERK activation, the subcellular location of KSR was determined. To detect KSR in live cells, GFP was fused to the amino terminus of KSR (GFP-KSR). We had previously observed the ability of ectopic KSR to inhibit ERK activation (14) . To confirm that the fusion of GFP did not alter the ability of KSR to regulate ERK activity, GFP-KSR was cotransfected with Raf-CAAX (a constitutively active form of Raf) into 293T cells, and ERK activity was measured in an immune complex kinase assay. Ectopic expression of GFP-KSR inhibited ERK activity in a manner similar to KSR (Fig. 1) , suggesting that the fusion of GFP does not affect the ability of KSR to regulate ERK activity. Fluorescence microscopy revealed that, at steady state, GFP-KSR microinjected into REF-52 cells was located in the cytoplasm in the majority of cells (Fig. 2B) cytoplasmic distribution as KSR without GFP attached ( Fig. 2A) .
A small number of REF-52 cells expressing GFP-KSR had nuclear fluorescence. This observation led us to determine whether wild-type KSR undergoes nucleocytoplasmic shuttling. To test this possibility, we treated REF-52 cells expressing GFP-KSR with leptomycin B, an inhibitor of Crm1-mediated nuclear export (35) . Upon treatment with 10 nM leptomycin B for 2 h, ϳ40% of the cells had nuclear fluorescence (Fig. 2 , B and C); and importantly, few of the cells contained GFP-KSR exclusively in the cytoplasm. The localization of GFP alone did not change upon treatment with leptomycin B in control experiments (data not shown). This observation demonstrates that KSR cycles continuously in and out of the nucleus.
Mutation of Phosphorylation Sites T274V and S392A Causes Nuclear Localization of KSR-KSR is phosphorylated on multiple phosphorylation sites (16, 33) . To determine whether phosphorylation of KSR regulates its subcellular localization, nine of the phosphorylation sites were mutated to non-phosphorylatable residues, and this mutant (GFP-KSR.9mut) was microinjected into REF-52 cells. Fluorescence microscopy revealed that KSR was located in the nucleus (data not shown). To ascertain which phosphorylation sites are important for nucleocytoplasmic transport, GFP fusion constructs of KSR mutants lacking six (6mut), five (5mut), and four (4mut) of the previously identified phosphorylation sites were created and expressed in REF-52 cells. The cells were then scored for nuclear fluorescence (Fig. 3B) . Intact KSR was localized exclusively to the cytoplasm (Fig. 3A) . However, 75-80% of the cells expressing 6mut, 5mut, or 4mut showed nuclear localization (Fig. 3B) .
To determine which of the phosphorylation sites in GFP-KSR.4mut (T274V/S392A/T411V/S518A) are most important for nuclear localization, all possible single and double phosphorylation mutants were created and expressed in REF-52 cells. The most dramatic shift was seen in cells expressing T274V/ S392A, with 80% of the cells showing nuclear fluorescence (Fig.  3, A and B) . The individual mutations T274V and S392A had a modest ability to cause nuclear localization of KSR (Fig. 3B ). However, a dramatic redistribution of KSR from the cytoplasm to the nucleus was seen upon combining these two mutations.
To determine whether Thr 274 Results are presented as the means Ϯ S.D. of three independent experiments for each construct. The S297A and S190A/S297A mutations were added to 4mut to construct 5mut and 6mut, respectively. C, the Thr 274 or Ser 392 phosphorylation site or both Thr 274 and Ser 392 were reintroduced to the backbone of a KSR construct containing nine mutated phosphorylation sites (KSR.9mut). KSR.9mut contains the mutated phosphorylation sites S429A, S430A, S431A, S320A, S434A, and S435A, in addition to the mutated sites contained in KSR.6mut as described above. Cells expressing KSR.9mut, KSR.9mutV274T, KSR.9mutA392S, or KSR.9mutV274T/A392S were scored, and the percentage of cells with nuclear fluorescence is shown. The total number of cells scored for each mutant is shown above each bar. Results are presented as the means Ϯ S.D. of three independent experiments. KSR.9mutA392S) or together (KSR.9mutV274T/A392S) reduced the nuclear localization of KSR by 20 -40%, but did not completely prevent its nuclear transport (Fig. 3C ). These data suggest that Thr 274 and Ser 392 are potent regulators of KSR subcellular localization, but they are not the sole determinants of KSR nucleocytoplasmic transport.
Mutations R589M and C809Y Abrogate Nucleocytoplasmic Shuttling-The KSR kinase domain binds MEK (10 -13). KSR.R589M has reduced ability to bind MEK1, and KSR.C809Y does not bind wild-type MEK1 (12, 13) . KSR.R589M is a predicted kinase-dead mutation (7), and KSR.C809Y is analogous to a loss-of-function mutation of KSR identified in C. elegans (5) . To determine whether these mutations in KSR affect nucleocytoplasmic transport, REF-52 cells expressing GFP-KSR.R589M and GFP-KSR.C809Y were treated with 10 nM leptomycin B for 2 h. In quiescent REF-52 cells, GFP-KSR.R589M and GFP-KSR.C809Y were located in the cytoplasm (Fig. 4A, panels 1, 3 , and 5). In contrast to wild-type KSR, treatment with leptomycin B failed to significantly increase the nuclear accumulation of GFP-KSR.C809Y; however, there was a slight increase in nuclear accumulation in cells expressing GFP-KSR.R589M (Fig. 4, A,  panels 2, 4, and 6; and B) . These data indicate that mutations R589M and C809Y inhibit the nucleocytoplasmic shuttling of KSR.
To determine whether there is a correlation between regulation of ERK activity by KSR and the ability of KSR to shuttle through the nucleus, we assessed the ability of KSR.R589M and KSR.C809Y to regulate ERK activation. KSR, KSR.R589M, and KSR.C809Y were cotransfected with Raf-CAAX into 293T cells, and ERK activity was measured. Wildtype KSR inhibited 90% of ERK activation by Raf-CAAX; ectopic expression of KSR.R589M inhibited only 50% of ERK activation; and KSR.C809Y had no effect on ERK activation (Fig. 4C) .
We further assessed the dependence of nuclear translocation of KSR on its interaction with MEK by creating a KSR construct containing the R589M, T274V, and S392A mutations. We observed that R589M was dominant with respect to the nuclear localizing effects of the phosphorylation site mutations (Fig. 5) . These data suggest a relationship between the subcellular distribution of KSR, its ability to interact with MEK, and its ability to regulate ERK activity.
Addition of the SV40 NLS Targets KSR to the Nucleus-The sequence PKKKRKV from the SV40 large T antigen (34) was spliced by PCR to the carboxyl-terminal end of CFP-KSR (CFP-KSR.NLS), CFP-KSR.R589M (CFP-KSR.R589MNLS), and CFP-KSR.C809Y (CFP-KSR.C809YNLS) (Fig. 6A) . These constructs were then expressed in REF-52 cells, and their subcellular localization was detected by fluorescence microscopy. All three NLS constructs were located exclusively in the nucleus (Fig. 6B) .
To determine whether the nuclear localization of KSR alters its ability to inhibit ERK activation, we performed ERK kinase assays on lysates from cells transfected with activated Raf-CAAX alone or with KSR constructs targeted to the nucleus. Mutation of phosphorylation sites on KSR that redistribute KSR to the nucleus or the addition of an NLS to wild-type KSR had little if any effect on its ability to inhibit ERK activation (Fig. 7) .
MEK1 Re-localizes KSR.NLS and KSR.T274V/S392A to the Cytoplasm-It has been reported that MEK accumulates in the nucleus upon treatment with leptomycin B (31), suggesting that MEK undergoes nucleocytoplasmic transport. Because KSR also undergoes nucleocytoplasmic transport and KSR and MEK interact, we sought to determine whether MEK plays a role in the nucleocytoplasmic transport of KSR. We analyzed the effect of MEK1 coexpression on the subcellular localization of KSR constructs targeted to specific subcellular compartments. To perform this analysis, YFP was fused to the amino terminus of MEK1, and CFP was added to the amino terminus of each KSR construct. This strategy enabled us to determine the subcellular location of MEK1 and KSR proteins simultaneously. When expressed together, YFP-MEK1 and CFP-KSR were located in the cytoplasm (data not shown). KSR.NLS constructs were coexpressed with YFP-MEK1 to evaluate the effect of MEK1 on KSR subcellular distribution. YFP-MEK1 remained in the cytoplasm when coexpressed with all KSR.NLS constructs and the KSR phosphorylation mutant CFP-KSR.T274V/S392A (Fig. 8, A and C) . However, in the same cells, expression of YFP-MEK1 caused a marked redistribution of CFP-KSR.T274V/S392A from the nucleus to the cytoplasm (Fig. 8C) . Furthermore, coexpression of YFP-MEK1 with CFP-KSR.NLS caused a redistribution of CFP-KSR.NLS from the nucleus to the cytoplasm. When coexpressed with YFP-MEK1, CFP-KSR.NLS was nuclear in only 25% of the cells compared with 98% of the cells when CFP-KSR.NLS was expressed alone (Fig. 8D) . These data suggest that MEK could enhance nuclear export and/or inhibit nuclear import of KSR. However, additional data suggest that it is unlikely that interaction with MEK inhibits KSR nuclear import. First, CFP-KSR.NLS accumulated in the nucleus of cells cotransfected with YFP-MEK1 and treated with leptomycin B (data not shown). Second, the C809Y and R589M mutations, which inhibit KSR association with MEK (12, 13) , also prevented the nuclear import of KSR (Fig. 4) . Therefore, it is more likely that interaction with MEK enhances KSR nuclear export.
KSR.NLS and KSR.T274V/S392A Bind to MEK-To support the possibility that the re-localization of KSR.NLS and KSR.T274V/S392A from the nucleus to the cytoplasm upon coexpression with YFP-MEK1 was due to protein/protein interaction, co-immunoprecipitation experiments were performed. CFP-KSR.NLS, CFP-KSR.C809YNLS, and CFP-KSR.T274V/ S392A were cotransfected with YFP-MEK1 into 293T cells. The cells were lysed and immunoprecipitated with anti-MEK antibody, and Western blotting was performed with monoclonal anti-GFP antibody, which also recognizes CFP and YFP (Fig.  9) . The anti-GFP blot revealed that KSR.NLS and KSR.T274V/ S392A co-immunoprecipitated with YFP-MEK1, consistent with the notion that cytoplasmic re-localization of KSR.NLS and KSR.T274V/S392A was mediated by direct interaction with MEK1. This conclusion is supported by the observation that KSR.C809YNLS did not co-precipitate with YFP-MEK1 and remained in the nucleus when coexpressed with YFP-MEK1 (Fig. 8) .
KSR Re-localizes MEK1.⌬NES to the Cytoplasm-We examined whether the subcellular location of MEK1 alters its ability to affect the distribution of KSR in cells. MEK1 accumulates in the nucleus upon treatment with leptomycin B (31), suggesting that MEK1 shuttles in and out of the nucleus. An NES has been identified in the amino terminus (amino acids 32-44) of MEK1, and deletion of this region causes MEK1 to accumulate in the nucleus (31) . Together with previous data showing that mutations KSR.R589M and KSR.C809Y affect binding to MEK1 (12, 13) , these data suggest a potential relationship between the nucleocytoplasmic transport of KSR and its ability to interact with MEK. To determine whether localizing MEK1 to the nucleus would cause redistribution of KSR, the NES in (Fig. 10) . Importantly, no cells were found to contain YFP-MEK1.⌬NES exclusively in the cytoplasm (Fig. 10A ). When coexpressed with YFP-MEK1.⌬NES, the subcellular distribution of all CFP-KSR constructs did not significantly change (Fig. 10, B and E) . However, CFP-KSR caused a redistribution of YFP-MEK1.⌬NES from the nucleus to the cytoplasm (Fig. 10, B and  D) . CFP-KSR.R589M had a similar effect on re-localizing YFP-MEK1.⌬NES from the nucleus to the cytoplasm (Fig. 10D) , indicating that a KSR mutant with reduced binding to MEK1 is still sufficient to affect the localization of YFP-MEK1.⌬NES. However, coexpression of CFP-KSR.C809Y did not affect the localization of YFP-MEK1.⌬NES, suggesting that a direct association between KSR and MEK causes the redistribution of MEK1 to the cytoplasm.
Cytoplasmic forms of MEK1 redistributed KSR.NLS from the nucleus to the cytoplasm (Fig. 8) . Similarly, coexpression of KSR re-localized MEK1.⌬NES from the nucleus to the cytoplasm (Fig. 10) . These data raise the possibility that KSR and MEK interact preferentially in the cytoplasm. To determine whether KSR and MEK1 interact in the nucleus, YFP-MEK1.⌬NES and CFP-KSR.NLS were coexpressed in REF-52 cells. We found that coexpression of CFP-KSR.NLS enhanced the nuclear localization of YFP-MEK1.⌬NES, whereas coexpression of CFP-KSR.C809YNLS had no effect on YFP-MEK1.⌬NES localization (Fig. 10, C and E) . These data suggest that KSR and MEK1 can also interact in the nucleus.
DISCUSSION
The subcellular localization of components that compose signal transduction pathways has become an important focus in elucidating the mechanisms by which these pathways are regulated. KSR is an important regulator of the Raf/MEK/ERK kinase cascade (4 -6, 8 -10, 14, 16, 36) . To gain insight into the mechanism by which KSR regulates ERK activation, we examined the subcellular localization of KSR. We found that KSR was localized to the cytoplasm of quiescent cells. The observation that a few cells expressing GFP-KSR had nuclear fluorescence led us to determine whether wild-type KSR undergoes nucleocytoplasmic shuttling. Treatment of REF-52 cells expressing GFP-KSR with leptomycin B, an inhibitor of Crm1-mediated nuclear export, caused GFP-KSR to accumulate in the nucleus of cells, suggesting that KSR is transported continuously in and out of the nucleus in quiescent cells.
Several phosphorylation sites have been identified on KSR (16, 33) . Of the phosphorylation sites identified, mutation of Thr 274 and Ser 392 caused KSR to localize to the nucleus (Fig. 3) . Phosphorylation of Ser 297 and Ser 392 regulates the interaction of KSR with 14-3-3 proteins (9, 16). Our observation that KSR.T274V/S392A was preferentially located in the nucleus implicates 14-3-3 as a regulator of KSR subcellular distribution. 14-3-3 functions in a similar manner to sequester the protein phosphatase Cdc25C (37), the forkhead transcription factor FHKRL1 (38) , and Raf (39, 40) . Combined mutation of Ser 297 and Ser 392 enhanced nuclear translocation of KSR (Fig.  3B) ; however, the nuclear shift was comparable to mutation of Ser 392 alone, suggesting that Ser 392 may be more important for cytoplasmic retention of KSR through interaction with 14-3-3.
To (16) , but the subcellular location at which this phosphorylation occurs is not known. It is possible that phosphorylation of Thr 274 facilitates export of KSR from the nucleus. In this case, KSR.T274V/S392A may be localized to the nucleus because of increased nuclear import due to loss of 14-3-3 binding and decreased nuclear export due to loss of phosphorylation on Thr 274 . KSR is located in the cytoplasmic fraction and moves to the membrane upon stimulation with serum or platelet-derived growth factor (9, 41) or in the presence of activated Ras (8) . In combination with the demonstration of KSR nuclear shuttling, these data suggest a mechanism similar to that affecting Ste5, a MAPK pathway scaffold in Saccharomyces cerevisiae. Ste5 continuously shuttles through the nucleus and translocates to the cell membrane upon pheromone stimulation (42) . Ste5 proteins that do not cycle through the nucleus are unable to translocate to the cell membrane and inhibit activation of the MAPK pathway. Conversely, Ste5 with enhanced ability to cycle through the nucleus has an increased ability to localize to the cell membrane and to activate the pathway (42) . It is intriguing to speculate that, like Ste5, KSR must cycle through the nucleus before translocating to the cell membrane upon mitogen stimulation.
Similar to KSR, MEK accumulates in the nucleus of quiescent cells upon treatment with leptomycin B (31), suggesting that MEK also shuttles continuously in and out of the nucleus. MEK contains an NES in its amino-terminal region that keeps MEK localized to the cytoplasm in quiescent cells (43, 44) . Disruption of MEK subcellular localization may be the mechanism by which ectopic KSR inhibits ERK activation (7, 11, 14) .
We hypothesize that KSR is a scaffold that regulates signaling through the Raf/MEK/ERK kinase cascade by regulating the subcellular distribution of MEK. KSR.C809Y does not bind MEK (12, 13) , translocate to the nucleus (Fig. 8, A and B) , or regulate ERK activity (Fig. 4C) , suggesting a possible link between these different effects of KSR. We examined the role KSR may play in regulating MEK nuclear localization. We found that KSR constructs localized to the nucleus were relocalized to the cytoplasm when coexpressed with MEK1. Redistribution of KSR to the cytoplasm was also dependent on MEK binding. Thus, KSR.NLS and KSR.T274V/S392A, which both bound MEK1 (Fig. 9) , redistribute from the nucleus to the cytoplasm upon coexpression with MEK1. Overexpression of MEK could indirectly affect KSR subcellular distribution. However, data that MEK coexpression does not alter the distribution of KSR.C809YNLS argue against this possibility because this construct did not bind MEK (Fig. 9 ). In addition, KSR.R589MNLS, a mutant with reduced MEK binding, showed an intermediate shift to the cytoplasm when coexpressed with MEK1. These observations suggest that a direct interaction between KSR and MEK affects the cytoplasmic distribution of KSR.
To determine whether altering the localization of MEK affects the location of KSR in REF-52 cells, we deleted the NES (amino acids 32-51) in MEK and fused YFP to the amino terminus (YFP-MEK.⌬NES). Greater than 50% of the cells had YFP-MEK.⌬NES preferentially located in the nucleus. Ectopic expression of any CFP-KSR construct able to bind MEK caused YFP-MEK.⌬NES to relocate to the cytoplasm. However, CFP-KSR.C809Y did not cause this re-localization. These studies indicate that interaction between KSR and MEK is critical in determining each protein's localization and suggest a potential role for KSR in the nuclear export of MEK. From these studies, it is unclear what role KSR may play in MEK export. One possibility is that KSR is exported with MEK. Although no NES has been identified, KSR does contain two regions that resemble leucine-rich NES motifs. The spacing of leucine/hydrophobic amino acids between amino acids 45 and 56 (LIDIS-IGSLRGL) and amino acids 827 and 837 (LERLPKLNRRL) resembles a consensus leucine-rich NES (45) . Mutation of these regions may provide further insight into the role of KSR in MEK nucleocytoplasmic transport and signaling.
A popular model suggests that the intensity and duration of signaling through the Raf/MEK/ERK kinase cascade determine the nucleocytoplasmic distribution of ERKs and the subsequent response of a cell to the activation of this pathway (46) . Ectopic expression of KSR at low levels has been reported to sustain ERK activation in epidermal growth factor-treated PC12 cells, with a coincident shift in cell responsiveness from proliferation to differentiation (13) . Our observation that KSR translocates to the nucleus raises the intriguing possibility that it may affect the cellular response to activation of the MAPK pathway by affecting the subcellular distribution of key effectors within this pathway. If correct, identifying the regulators of KSR subcellular distribution may reveal important modifiers of MAPK signaling.
